Detalles de la búsqueda
1.
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.
Lancet Oncol
; 2024 Jun 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38889735
2.
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(10): 1378-1390, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34529931
3.
Role of eHealth application Oncokompas in supporting self-management of symptoms and health-related quality of life in cancer survivors: a randomised, controlled trial.
Lancet Oncol
; 21(1): 80-94, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31838009
4.
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Lancet
; 394(10192): 29-38, 2019 07 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31171419
5.
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study.
Haematologica
; 105(6): 1650-1659, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31515355
6.
Two-sided femoral Campylobacter jejuni osteomyelitis in a patient with acquired hypogammaglobulinemia: a case report.
BMC Infect Dis
; 20(1): 199, 2020 Mar 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32143636
7.
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
Blood
; 127(9): 1109-16, 2016 Mar 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-26802176
8.
Severe cutis laxa caused by immunoglobulin M gammopathy.
Br J Haematol
; 196(4): 802, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34761386
9.
Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study.
Haematologica
; 106(8): 2257-2260, 2021 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33657786
10.
Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial.
EClinicalMedicine
; 63: 102167, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37680948
11.
Ruxolitinib in Myelofibrosis and Baseline Thrombocytopenia in Real Life: Results in Dutch Patients and Review of the Literature.
Clin Lymphoma Myeloma Leuk
; 19(10): 624-634, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31427260
12.
Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands.
Blood Cancer J
; 12(3): 41, 2022 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35292622
13.
Improving the identification of frail elderly newly diagnosed multiple myeloma patients.
Leukemia
; 35(9): 2715-2719, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33589752
14.
[A woman with fatigue and teardrop cells]. / Een vermoeide vrouw met traandruppelcellen.
Ned Tijdschr Geneeskd
; 157(52): A6905, 2013.
Artículo
en Neerlandesa
| MEDLINE | ID: mdl-24382042
Resultados
1 -
14
de 14
1
Próxima >
>>